Atlanta, GA — September 18, 2025 — Leads & Copy — GeoVax Labs, Inc. (Nasdaq: GOVX) announced its presentation at the Emerging Growth Conference on September 25, 2025, highlighting positive interim clinical results for its COVID-19 vaccine candidate, GEO-CM04S1. The data, presented at iwCLL 2025 and ESCMID 2025, demonstrated the vaccine’s efficacy in immunocompromised patients, including those with chronic lymphocytic leukemia (CLL), blood cancer, and post-transplant patients.
The Phase 2 data in CLL patients showed that CM04S1 achieved the study’s immune response primary endpoint, while the comparator mRNA vaccine did not. Interim results also demonstrated robust, durable T-cell and cross-variant antibody responses, with no serious adverse events reported.
“These results underscore the promise of CM04S1 as a multi-antigen solution for patients left behind by first-generation COVID-19 vaccines,” said David Dodd, Chairman & CEO of GeoVax.
Mr. Dodd will present at the Emerging Growth Conference from 3:55 PM to 4:05 PM Eastern Time. A replay will be available on www.EmergingGrowth.com and YouTube.com/EmergingGrowthConference.
GeoVax Labs, Inc. is developing vaccines against infectious diseases and therapies for solid tumor cancers. Its lead clinical program, GEO-CM04S1, is in Phase 2 clinical trials.
Company Contact:
info@geovax.com
678-384-7220
Media Contact:
Jessica Starman
media@geovax.com
Source: GeoVax Labs, Inc.
